Hassane M. Zarour
University of Pittsburgh(US)UPMC Hillman Cancer Center(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, CAR-T cell therapy research, Immune Cell Function and Interaction, Cutaneous Melanoma Detection and Management
Most-Cited Works
- → Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma(2013)3,383 cited
- → Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial(2014)1,753 cited
- → Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients(2021)1,511 cited
- → Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients(2010)1,276 cited
- → Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma(2016)1,053 cited
- → Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001(2019)928 cited